OncoMatch/Clinical Trials/NCT07637448
EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
Is NCT07637448 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2 trial studies EGFR-TKIs Combined with PD-1 Monoclonal Antibody for lung cancer non-small cell cancer (nsclc).
Treatment: EGFR-TKIs Combined with PD-1 Monoclonal Antibody — This study is an open-label, multicenter, single-arm clinical study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
EGFR-mutant (19del/L858R)
Required: EGFR l858r
EGFR-mutant (19del/L858R)
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Prior therapy
Cannot have received: anti-pd-1/pd-l1 immunotherapy
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07637448 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR exon 19 deletion is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR l858r is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages